TY - JOUR
T1 - Biomolecular interactions with nanoparticles
T2 - applications for coronavirus disease 2019
AU - Farouq, Mohammed A.H.
AU - Al Qaraghuli, Mohammed M.
AU - Kubiak-Ossowska, Karina
AU - Ferro, Valerie A.
AU - Mulheran, Paul A.
PY - 2021/8/31
Y1 - 2021/8/31
N2 - Nanoparticles are small particles sized 1–100 nm, which have a large surface-to-volume ratio, allowing efficient adsorption of drugs, proteins, and other chemical compounds. Consequently, functionalized nanoparticles have potential diagnostic and therapeutic applications. A variety of nanoparticles have been studied, including those constructed from inorganic materials, biopolymers, and lipids. In this review, we focus on recent work targeting the severe acute respiratory syndrome coronavirus 2 virus that causes coronavirus disease (COVID-19). Understanding the interactions between coronavirus-specific proteins (such as the spike protein and its host cell receptor angiotensin-converting enzyme 2) with different nanoparticles paves the way to the development of new therapeutics and diagnostics that are urgently needed for the fight against COVID-19, and indeed for related future viral threats that may emerge.
AB - Nanoparticles are small particles sized 1–100 nm, which have a large surface-to-volume ratio, allowing efficient adsorption of drugs, proteins, and other chemical compounds. Consequently, functionalized nanoparticles have potential diagnostic and therapeutic applications. A variety of nanoparticles have been studied, including those constructed from inorganic materials, biopolymers, and lipids. In this review, we focus on recent work targeting the severe acute respiratory syndrome coronavirus 2 virus that causes coronavirus disease (COVID-19). Understanding the interactions between coronavirus-specific proteins (such as the spike protein and its host cell receptor angiotensin-converting enzyme 2) with different nanoparticles paves the way to the development of new therapeutics and diagnostics that are urgently needed for the fight against COVID-19, and indeed for related future viral threats that may emerge.
KW - COVID-19
KW - diagnostics
KW - therapeutics
KW - proteins
KW - SARS-CoV-2
KW - nanoparticles
U2 - 10.1016/j.cocis.2021.101461
DO - 10.1016/j.cocis.2021.101461
M3 - Review article
VL - 54
JO - Current Opinion in Colloid and Interface Science
JF - Current Opinion in Colloid and Interface Science
SN - 1359-0294
M1 - 101461
ER -